Zak Mir talks to Anthony Tennyson, CEO, and Professor David Nutt, CSO, Solvonis Therapeutics regarding the clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. The latest announcement at Solvonis is the initiation of an AI supported drug discovery programme focused on its proprietary central nervous system compound library.
Author
